For the latest
cancer COVID-19 resources, click on this link
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
Brain & nervous system
Karolinska Institute, Sweden
12 - 16 Sep 2008
Please rate this video
The information in this video was of interest to me
The information in this video is likely to improve my clinical practice or research
I would recommend this video to my colleagues
Published: 4 Dec 2008
Prof. Matthias Löhr
New drug substantially extends survival in pancreatic cancer.
Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocell...
Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA
13 Apr 2021
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than l...
Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA
13 Apr 2021
High-quality neoantigens are immunoedited in long-term survivors of pancreatic c...
Prof Marta Luksza - Tisch Cancer Institute, New York, USA
12 Apr 2021
Targeting a KRAS neoantigen peptide vaccine to DNGR-1 dendritic cells
Dr Rachel Ambler - The Francis Crick Institute, London, United Kingdom
27 Nov 2020
Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more...
Prof Federico Innocenti - University of North Carolina, Chapel Hill, USA
4 Nov 2020
Updates in geriatric medical oncology from SIOG meeting
Dr Enrique Soto - Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zu...
28 Oct 2020
OncoAlert and ecancer weekly roundup for August 17-23 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
24 Aug 2020